Johnson & Johnson raises outlook after Q2 sales growth.
Johnson & Johnson raised its full-year outlook on Wednesday after second-quarter sales rose 6.6% to $25.31bn, ahead of market expectations, while adjusted earnings increased 4.7% to $2.90 per share.
Johnson & Johnson
15 July 2026 16:17:33
Source: Sharecast
Innovative Medicine sales grew 7.8% to $16.38bn, driven by strong demand for Tremfya, Darzalex, Carvykti and Caplyta, offsetting declines in older products including Stelara, while MedTech sales rose 4.5% to $8.93bn.
The healthcare group now expects 2026 reported sales of $100.8bn to $101.4bn and adjusted earnings of $11.60 to $11.75 per share, raising the midpoints to $101.1bn and $11.68 respectively.
Chief executive Joaquin Duato said Johnson & Johnson was on track to exceed $100bn of annual revenue for the first time in its 140-year history.
At 1114 EDT (1614 BST), shares in Johonson & Johnson were down 0.6% in New York at $252.32.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
